HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA requests recall of two men’s energy supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA requests a recall of True Man Sexual Energy Nutrient Capsules and Energy Max Energy Supplement Men's Formula Capsules because they contain potentially harmful and undeclared ingredients, the agency announces Nov. 2. The products are advertised as being "all natural" alternatives to FDA-approved erectile dysfunction drugs, but could interact with medications and cause low blood pressure because True Man and Energy Max contain analogs of sildenafil and vardenafil, the active ingredients in Pfizer's Viagra and GlaxoSmithKiline's/Schering-Plough's Levitra, respectively. FDA repeatedly has said its plans to ramp up enforcement against companies using drug ingredients in supplements (1"The Tan Sheet" Oct. 15, 2007, p. 3)...

You may also be interested in...



FDA Plans To Step Up Enforcement Actions On Supplement Rx Contaminants

FDA anticipates media coverage of its enforcement actions against firms marketing illegal supplement products will benefit responsible members of the industry, according to Center for Food Safety and Applied Nutrition Director Robert E. Brackett

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel